Home > Insider Trading > Filing (0001104659-24-004540)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1442836	Mersana Therapeutics Inc.	MRSN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1991787	Mohan Bala	C/O Mersana Therapeutics, Inc. 840 Memorial Drive Cambridge MA 02139	Svp, Chief Development Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-01-13	8,750	$0.00	17,483	No	4	M	Direct
Common Stock	Disposition	2024-01-16	3,431	$2.71	14,052	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Unit	Disposition	2024-01-13	8,750	$0.00	8,750	$0.00
Common Stock	Stock Option (Right to Buy)	Acquisiton	2024-01-15	262,500	$0.00	262,500	$3.02
Common Stock	Restricted Stock Unit	Acquisiton	2024-01-15	58,333	$0.00	58,333	$0.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
26,250		No	4	M	Direct
262,500	2034-01-14	No	4	A	Direct
58,333		No	4	A	Direct

Footnotes

Represents shares of common stock received upon vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on January 13, 2023.
Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2023. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the Reporting Person.
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $2.70 to $2.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Each RSU represents the contingent right to receive one share of common stock of the Issuer.
25% of the total number of RSUs granted vested on January 13, 2024, and the remainder shall vest thereafter in equal annual installments over the next three years.
The option shall vest in equal quarterly installments over four years from the date of grant.
The RSUs shall vest in equal annual installments over four years from the date of grant.